Clinical Trial Update: EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis [Phase 4]

View source ↗

Summary

A Phase 4 trial (EFFICACI) comparing intravenous infliximab versus vedolizumab in ulcerative colitis patients after failure of subcutaneous anti-TNFs; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Infliximab (infliximab)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: Rennes University Hospital | Conditions: Ulcerative Colitis | Phase 4 | Status: COMPLETED